Syntara Reports Encouraging Interim Results from Phase 2 Trial
Syntara (ASX:SNT) has released promising interim results from its Phase 2 study of SNT-4728, marking a significant milestone in the development of a novel anti-inflammatory therapy that could target key biological processes associated with Parkinson’s disease. This is the first clinical evidence suggesting that the company’s treatment may be addressing a critical aspect of the disease’s progression.
The trial focuses on patients with isolated REM Sleep Behaviour Disorder (iRBD), a condition that is considered a strong risk factor for developing Parkinson’s disease or related disorders. The study is the world’s first interventional trial targeting neuroinflammation directly in this patient population. Neuroinflammation is increasingly seen as a major contributor to neurodegenerative diseases.
Key Findings from the Study
The preliminary analysis showed a statistically significant reduction in brain inflammation within the putamen, a region of the brain closely linked to the movement symptoms of Parkinson’s disease. Out of 30 patients treated with SNT-4728, 20 experienced a decrease in inflammation after just 12 weeks of treatment.
Notably, the drug maintained a favorable safety profile throughout the study, with no serious adverse events reported. These findings represent an important proof-of-concept, indicating that SNT-4728 may be influencing disease-relevant neuroinflammatory pathways.
Professor Simon Lewis, Director of the Parkinson’s Disease Research Clinic at Macquarie University and a principal investigator on the study, described the results as “notable.” He highlighted that detecting measurable biological changes after only three months of treatment in a population that typically takes over a decade to develop Parkinson’s symptoms is a positive sign.
Future Steps and Clinical Development
Syntara expects to release the full dataset later in Q3 2026. This will include additional brain imaging, digital, and biological biomarkers, which are expected to provide a more comprehensive understanding of the drug’s activity and guide the next phase of clinical development.
Based on the emerging data, Syntara has also filed a new provisional patent application covering SNT-4728 in iRBD. This underscores the company’s confidence in the potential of the drug to address a significant unmet medical need.
Implications for Investors
For investors, the interim analysis represents an encouraging first step in what could become a first-in-class therapy aimed not just at treating Parkinson’s symptoms but at slowing the disease process years before clinical diagnosis.
With more data still to come, SNT-4728 remains one of several significant clinical catalysts expected from Syntara’s pipeline during 2026. The progress made so far highlights the company’s commitment to advancing innovative treatments for neurodegenerative diseases.
Join the Discussion
Stay informed about the latest developments in the stock market by joining the conversations on HotCopper, Australia’s largest stock forum. Engage with other investors and traders to gain insights into trending topics and market movements.
Disclaimer
This content has been prepared as part of a partnership with Syntara Ltd and is intended for informational purposes only. The material provided in this article is for information only and should not be treated as investment advice. Viewers are encouraged to conduct their own research and consult with a certified financial advisor before making any investment decisions. For full disclaimer information, please click here.
